title: Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways.
abstract: This study examined the role of endocannabinoid signaling in stress-induced reinstatement of cocaine seeking and explored the interaction between noradrenergic and endocannabinergic systems in the process. A well-validated preclinical model for human relapse, the rodent conditioned place preference assay, was used. Cocaine-induced place preference was established in C57BL/6 mice using injections of 15 mg/kg cocaine. Following extinction of preference for the cocaine-paired environment, reinstatement of place preference was determined following 6 min of swim stress or cocaine injection (15 mg/kg, i.p.). The role of endocannabinoid signaling was studied using the cannabinoid antagonist AM-251 (3 mg/kg, i.p.). Another cohort of mice was tested for reinstatement following administration of the cannabinoid agonist CP 55,940 (10, 20, or 40 μg/kg, i.p.). The alpha-2 adrenergic antagonist BRL-44408 (5 mg/kg, i.p.) with or without CP 55,940 (20 μg/kg) was administered to a third group of mice. We found that: (1) AM-251 blocked forced swim-induced, but not cocaine-induced, reinstatement of cocaine-seeking behavior; (2) the cannabinoid agonist CP 55,940 did not reinstate cocaine-seeking behavior when administered alone but did synergize with a non-reinstating dose of the alpha-2 adrenergic antagonist BRL-44408 to cause reinstatement. These results are consistent with the hypothesis that stress exposure triggers the endogenous activation of CB1 receptors and that activation of the endocannabinoid system is required for the stress-induced relapse of the mice to cocaine seeking. Further, the data suggest that the endocannabinoid system interacts with noradrenergic mechanisms to influence stress-induced reinstatement of cocaine-seeking behavior.
authors.affiliation: Department of Biomedical Sciences, Marquette University, Milwaukee, WI 53233, USA. Linda.Vaughn@mu.edu
authors.forename: L K
authors.initials: LK
authors.lastname: Vaughn
authors.forename: J R
authors.initials: JR
authors.lastname: Mantsch
authors.forename: O
authors.initials: O
authors.lastname: Vranjkovic
authors.forename: G
authors.initials: G
authors.lastname: Stroh
authors.forename: M
authors.initials: M
authors.lastname: Lacourt
authors.forename: M
authors.initials: M
authors.lastname: Kreutter
authors.forename: C J
authors.initials: CJ
authors.lastname: Hillard
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D016739:Behavior, Addictive / Q000139:chemically induced; D002186:Cannabinoids / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology*; D003213:Conditioning, Psychological / Q000187:drug effects*; D003511:Cyclohexanols / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D058999:Drug-Seeking Behavior / Q000187:drug effects*; D005108:Extinction, Psychological / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology; D054833:Isoindoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D012646:Self Administration; D013315:Stress, Psychological / Q000503:physiopathology*
chemical_list: D000317:Adrenergic alpha-Antagonists; D002186:Cannabinoids; D003511:Cyclohexanols; D018765:Dopamine Uptake Inhibitors; D007093:Imidazoles; D054833:Isoindoles; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D003042:Cocaine; C072125:BRL 44408